Laura Beth Kalvas

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Laura Beth Kalvas sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Laura Beth Kalvas: 1 sponsored US clinical trial, 1 recruiting.

Laura Beth Kalvas sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Pediatric Critical Illness, with 1 trials.

Mid-pack sponsor footprint

Laura Beth Kalvas is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

Feasibility of Light Therapy in the Pediatric Intensive Care Unit (ICU)

NCT07384585

Therapeutic Areas

Pediatric Critical Illness 1
Light Exposure 1
Circadian Dysregulation 1

What is open in the Laura Beth Kalvas pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Pediatric Critical Illness (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Laura Beth Kalvas: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Laura Beth Kalvas sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Laura Beth Kalvas1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Laura Beth Kalvas sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Laura Beth Kalvas sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Laura Beth Kalvas page

1 registered trials is a research-attention snapshot, not an endorsement of Laura Beth Kalvas or any single study.

  • 1 of Laura Beth Kalvas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pediatric Critical Illness is the condition Laura Beth Kalvas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pediatric Critical Illness trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Laura Beth Kalvas pipeline card: 1 registered trials from official public datasets.Report a data error.